(dengue and possibly RVF) have been reported in recent years in Somalia: RVF outbreaks occurred during 1997-1998 and 2006-2007 (6,7) , and a dengue outbreak occurred during 1992-1993 (8) .
The current outbreak in Somalia could have been triggered by several factors, including circulation of CHIKV in neighboring Kenya (references 8,9 in online Technical Appendix) and heavy rains that led to flooding in southern and central Somalia beginning in January 2016 (reference 1 in online Technical Appendix). CHIKV has the potential to provoke explosive outbreaks in naive populations (9) , so the current outbreak may greatly affect the economy and public health in Somalia.
Systematic studies to understand the magnitude of the ongoing epidemic are needed. In the meantime, local public health stakeholders in Somalia and healthcare workers worldwide caring for travelers returning from Somalia should be aware that CHIKV is circulating in the country. This report confirms the importance of travel medicine services in performing early diagnosis of imported arboviral diseases, not only to thwart secondary transmission during periods of competent vector activity but also to help to detect or confirm virus circulation in previously unaffected countries. The absence of a significant difference does not necessarily mean that the 2 vaccines have similar effectiveness. The incidence rate of meningococcal disease was 68% higher ([0.307-0.183] × 100/0.183) during the period of MPSV-4 use than during the period of MCV-4 use. If the same findings arose in a study of sufficient size to achieve statistical significance, this difference would be considered of substantial clinical importance. A happy consequence of the long-term temporal trends in meningococcal incidence and the success of these vaccines is that the incidence of meningococcal disease is now sufficiently reduced that even the very large active-duty population is too small to provide the statistical power to declare these 2 different incidence rates as being statistically different.
Meningococcal Disease in US Military
The trends reported by Broderick et al. have continued. During 2006-2014, the incidence of meningococcal disease caused by vaccine-covered serogroups among US military recipients of MCV-4 fell to 0.146 per 100,000 person-years, whereas MPVS-4-related incidence did not change (M.P. Broderick, pers. comm.). Furthermore, through July 2016, the US military has not seen a case from a covered serogroup since 2011 among recipients of MCV-4. Even with these additional data, however, the difference between MCV-4 and MPSV-4 does not achieve statistical significance (M.P. Broderick, pers. comm.).
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